Fig. 3.
Time to treatment failure (TTF) for nab-paclitaxel plus gemcitabine (nab-P + G) vs. FOLFIRINOX; Eastern Cooperative Oncology Group (ECOG) performance status 0–1
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.